Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Blood Cancer Discovery
|
September 17, 2025
The Two Sides of Bispecific Antibodies in Multiple Myeloma: Where Trial Promise Meets Real-World Practice
Sonja Zweegman, Febe Smits, Niels W C J van de Donk
The Journal of Hand Surgery
|
September 28, 2017
Outcome of Carpal Tunnel Release and the Relation With Depression
Mirjam Datema, Martijn R Tannemaat, Elske Hoitsma, et al.
Huisarts En Wetenschap
|
June 7, 2021
Febe Smits, Bart Torensma, Rolf Groenwold, et al.
Blood Cancer Journal
|
February 20, 2026
Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab
Febe Smits, Kaz Groen, Charlotte L B M Korst, et al.
Hemasphere
|
June 9, 2026
Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma
Gala Vega, Daniel Morillo, Christine Riedhammer, et al.
Eclinicalmedicine
|
November 17, 2025
Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial
Maarten R Seefat, Niek G van der Maas, Kazem Nasserinejad, et al.
Blood
|
August 19, 2025
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy
Wassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Hemasphere
|
July 5, 2024
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
Kazimierz Groen, Febe Smits, Kazem Nasserinejad, et al.
Hemasphere
|
October 7, 2025
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels
Wassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Hemasphere
|
December 10, 2025
Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
Kazimierz Groen, Febe Smits, Kazem Nasserinejad, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Blood Cancer Discovery
|
September 17, 2025
The Two Sides of Bispecific Antibodies in Multiple Myeloma: Where Trial Promise Meets Real-World Practice
Sonja Zweegman, Febe Smits, Niels W C J van de Donk
The Journal of Hand Surgery
|
September 28, 2017
Outcome of Carpal Tunnel Release and the Relation With Depression
Mirjam Datema, Martijn R Tannemaat, Elske Hoitsma, et al.
Huisarts En Wetenschap
|
June 7, 2021
Febe Smits, Bart Torensma, Rolf Groenwold, et al.
Blood Cancer Journal
|
February 20, 2026
Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab
Febe Smits, Kaz Groen, Charlotte L B M Korst, et al.
Hemasphere
|
June 9, 2026
Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma
Gala Vega, Daniel Morillo, Christine Riedhammer, et al.
Eclinicalmedicine
|
November 17, 2025
Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial
Maarten R Seefat, Niek G van der Maas, Kazem Nasserinejad, et al.
Blood
|
August 19, 2025
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy
Wassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Hemasphere
|
July 5, 2024
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
Kazimierz Groen, Febe Smits, Kazem Nasserinejad, et al.
Hemasphere
|
October 7, 2025
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels
Wassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Hemasphere
|
December 10, 2025
Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
Kazimierz Groen, Febe Smits, Kazem Nasserinejad, et al.
Page
of 2